Other single compounds
| Zeile 33: | Zeile 33: | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| Zeile 113: | Zeile 106: | ||
{{tp|p=32352081|t=ä. Perspectives for the use of therapeutic Botulinum toxin as a multifaceted candidate drug to attenuate COVID-19 |pdf=|usr=}} | {{tp|p=32352081|t=ä. Perspectives for the use of therapeutic Botulinum toxin as a multifaceted candidate drug to attenuate COVID-19 |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
| Zeile 131: | Zeile 121: | ||
{{tp|p=32353743|t=2020. Purposing Saikosaponins for the treatment of COVID-19 |pdf=|usr=}} | {{tp|p=32353743|t=2020. Purposing Saikosaponins for the treatment of COVID-19 |pdf=|usr=}} | ||
{{tp|p=32345124|t=2020. An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets |pdf=|usr=}} | {{tp|p=32345124|t=2020. An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
'''Clozapine''' | '''Clozapine''' | ||
| Zeile 185: | Zeile 166: | ||
'''Spironolactone''' | '''Spironolactone''' | ||
{{tp|p=32297520|t=2020. Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?|pdf=|usr=}} | {{tp|p=32297520|t=2020. Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?|pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
'''Luteolin''' | '''Luteolin''' | ||
{{tp|p=32339387|t=2020. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin |pdf=|usr=}} | {{tp|p=32339387|t=2020. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
'''Pannexin1 channels''' | '''Pannexin1 channels''' | ||
| Zeile 236: | Zeile 202: | ||
| − | |||
| − | |||
| Zeile 254: | Zeile 218: | ||
{{tp|p=32388480|t=2020. Can beta-adrenergic blockers be used in the treatment of COVID-19?|pdf=|usr=}} | {{tp|p=32388480|t=2020. Can beta-adrenergic blockers be used in the treatment of COVID-19?|pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
'''mabs''' | '''mabs''' | ||
| Zeile 311: | Zeile 231: | ||
{{tp|p=32391920|t=2020. Consider TLR5 for new therapeutic development against COVID-19.|pdf=|usr=008}} | {{tp|p=32391920|t=2020. Consider TLR5 for new therapeutic development against COVID-19.|pdf=|usr=008}} | ||
| − | |||
| − | |||
| − | |||
'''lactoferrin''' | '''lactoferrin''' | ||
| Zeile 358: | Zeile 275: | ||
{{tp|p=32473070|t=2020. Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?|pdf=|usr=007}} | {{tp|p=32473070|t=2020. Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?|pdf=|usr=007}} | ||
{{tp|p=32485316|t=2020. Pentoxifylline and complicated COVID-19: A pathophysiologically based treatment proposal.|pdf=|usr=009}} | {{tp|p=32485316|t=2020. Pentoxifylline and complicated COVID-19: A pathophysiologically based treatment proposal.|pdf=|usr=009}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
'''PARP inh''' | '''PARP inh''' | ||
| Zeile 381: | Zeile 291: | ||
'''Salinomycin''' | '''Salinomycin''' | ||
{{tp|p=32516655|t=2020. Pulmonary delivery of nanostructured lipid carriers for effective repurposing of salinomycin as an antiviral agent.|pdf=|usr=009}} | {{tp|p=32516655|t=2020. Pulmonary delivery of nanostructured lipid carriers for effective repurposing of salinomycin as an antiviral agent.|pdf=|usr=009}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
Version vom 8. Juli 2020, 08:05 Uhr
Thymosin
| 32442287 2020. Thymosin alpha 1 (Talpha1) reduces the mortality of severe COVID-19 by restoration of lymphocytopenia and reversion of exhausted T cells. |
G-CSF
32419212 2020. Granulocyte-colony stimulating factor in COVID-19: Is it stimulating more than just the bone marrow?
hzVSF‐v13
Humanized virus suppressing factor‐variant 13 (hzVSF‐v13) is a monoclonal IgG4 against vimentin, which is expressed on the surface of virus‐infected cells.
32458425 2020. Compassionate use of hzVSF-v13 in two patients with severe COVID-19.
Omalizumab
32510814 2020. Omalizumab and COVID19 Treatment: Could It Help? Anti-IgE mab, -IL6,-TNF,-IL1,-NFKB
Almitrine
32505756 2020. Almitrine as a non-ventilatory strategy to improve intrapulmonary shunt in COVID-19 patients.
32505755 2020. Effect of almitrine bismesylate and inhaled nitric oxide on oxygenation in COVID-19 acute respiratory distress syndrome.
32512007 2020. Efficacy of Almitrine in The Treatment of Hypoxemia in Sars-Cov-2 Acute Respiratory Distress Syndrome.
H2S
32515982 2020. H2S as a potential defence against COVID-19?
Oleoylethanolamide
32327293 ä. Oleoylethanolamide, A Bioactive Lipid Amide, as A Promising Treatment Strategy for Coronavirus/COVID-19
Lauric acid nat. compd.
Dipyridamole retarget
32318327 ä. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19
CGRP calcitonin gene related peptide antagonists
32386433 2020. Could CGRP Antagonists Be Helpful in the Fight Against COVID-19?
Various Leads
- 9 retargeted: ternatin4, zotatifin, plitidepsin; haloperidol, melperone, clemastine, cloperastine, pb28, progesterone
- paper in nature
32251767 2020. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
32226695 ä. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19)
BRD4 polycomb
32495654 2020. Targeting SARS-CoV-2 using polycomb inhibitors as antiviral agents.
Glycyrrhizin
32335281 ä. Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19
| 32077621 2020. Glycyrrhizic-Acid-Based Carbon Dots with High Antiviral Activity by Multisite Inhibition Mechanisms |
32458502 2020. Glycyrrhetinic acid and its derivatives as potential alternative medicine to relieve symptoms in nonhospitalized COVID-19 patients.
Ipecac
32245264 2020. Emetine, Ipecac, Ipecac Alkaloids and Analogues as Potential Antiviral Agents for Coronaviruses
Camostat mesilate serine proteinase inh
32347443 ä. Camostat mesilate therapy for COVID-19
32489508 2020. Simultaneous Treatment of COVID-19 With Serine Protease Inhibitor Camostat and/or Cathepsin L Inhibitor?
Nafamostat mesilate serine proteinase inh
32312781 2020. Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
32302456 2020. Potential of heparin and nafamostat combination therapy for COVID-19
32470602 2020. Three cases of treatment with Nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy.
Sodium pyruvate
32378817 2020. Inhaled Nebulized Sodium Pyruvate Use in COVID-19 Patients
alpha1 adrenergic antagonists
32352407 2020. Preventing cytokine storm syndrome in COVID-19 using alpha-1 adrenergic receptor antagonists
32237190 ä. What does androgenetic alopecia have to do with COVID?19? An insight into a potential new therapy
Ciclesonide
32362440 ä. Therapeutic potential of ciclesonide inhalation for COVID-19 pneumonia: Report of three cases
Melatonin
32217117 2020. COVID-19: Melatonin as a potential adjuvant treatment
32360622 2020. Comment on Melatonin as a potential adjuvant treatment for COVID-19
32334009 2020. Correspondence COVID-19: Melatonin as a potential adjuvant treatment
32347747 2020. Can melatonin reduce the severity of COVID-19 pandemic?
32314850 2020. Melatonin: Roles in influenza, Covid?19, and other viral infections
32422305 2020. Lungs as target of COVID-19 infection: Protective common molecular mechanisms of vitamin D and melatonin as a new potential synergistic treatment.
cannabinoids
32360437 ä. SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation?
32273254 2020. Cannabidiol as prophylaxis for SARS-CoV-2 and COVID-19? Unfounded claims versus potential risks of medications during the pandemic
32519753 2020. The potential of cannabidiol in the COVID-19 pandemic: a hypothesis letter.
32380847 2020. Cannabis in the Time of Coronavirus Disease 2019: The Yin and Yang of the Endocannabinoid System in Immunocompetence
32467020 2020. A...: Cannabidiol as a potential anti-inflammatory treatment? .
32471272 2020. Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?
Oxytocin
32344303 ä. Oxytocin as a potential defence against Covid-19?
Botox
32352081 ä. Perspectives for the use of therapeutic Botulinum toxin as a multifaceted candidate drug to attenuate COVID-19
Endothelin antagonists
32361169 2020. Why not consider an endothelin receptor antagonist against SARS?CoV?2?
32360293 2020. Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: Friend or foe?
Rho kinase inhibitors
32283223 2020. Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19)
Saikosaponins
32353743 2020. Purposing Saikosaponins for the treatment of COVID-19
32345124 2020. An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets
Clozapine
32475694 2020. Reflexions autour d'une evolution favorable d'une COVID-19 chez un patient presentant une schizophrenie resistante et sous une association clozapine et paliperidone palmitate.
Olanzapine
32344275 2020. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS)
ADAM17 as target
32291449 ä. ADAM17 inhibition may exert a protective effect on COVID-19
Dextrometorphan
Nitazoxanide
32405422 2020. Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19.
32360581 ä. Nitazoxanide/Azithromycin combination for COVID-19: A suggested new protocol for COVID-19 early management
tPA
| 32312290 2020. Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis |
| 31856018 2020. Is there a role for tissue plasminogen activator as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome? |
32427774 2020. Early Outcomes with Utilization of Tissue Plasminogen Activator in COVID-19 Associated Respiratory Distress: A series of five cases.
| 32427773 2020. Rescue Therapy for Severe COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with Tissue Plasminogen Activator (tPA): A Case Series. |
Plasminogen
32275753 ä. Plasminogen improves lung lesions and hypoxemia in patients with COVID-19
Hesperidin
32531538 2020. Is hesperidin essential for prophylaxis and treatment of COVID-19 Infection?
Diacerein
32534337 2020. Diacerein: A potential multi-target therapeutic drug for COVID-19.
CD147
32307653 ä. CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement
Bee venom
32360140 ä. Bee venom and SARS-CoV-2
Spironolactone
32297520 2020. Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?
Luteolin
32339387 2020. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin
Pannexin1 channels
32519892 2020. Consideration of Pannexin 1 channels in COVID-19 pathology and treatment.
NAD+
32534944 2020. Influence of NAD+ as an ageing-related immunomodulator on COVID 19 infection: A hypothesis.
Celastrol
32347602 2020. Should we try the antiinflammatory natural product, celastrol, for COVID-19?
1
32352871 2020. A Radiation Mitigator as a Potential Treatment for COVID-19
Ozone
C7203037 ä. (Vitamin-C; Ozone)Two known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19?
32462858 2020. Oxygen-ozone therapy as adjuvant in the current emergency in SARS-COV-2 infection: a clinical study.
stimulating the Platelets
| 32315397 2020. Promoting platelets is a therapeutic option to combat severe viral infection of the lung |
Thrombomodulin
23607598 2013. (x)Involvement of high mobility group box 1 and the therapeutic effect of recombinant thrombomodulin in a mouse model of severe acute respiratory distress syndrome
Chlorpromazine
32387014 ä. Repositionnement de la chlorpromazine ... psychiatric patients could be protected from severe forms of COVID-19 by their psychotropic treatments
Lipids
32345532 2020. Response to: Bioactive Lipids and Coronavirus (COVID-19)-further Discussion.
32429572 2020. The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target.
32408699 2020. Essential Oils as Antiviral Agents. Potential of Essential Oils to Treat SARS-CoV-2 Infection: An In-Silico Investigation.
32457038 2020. Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity.
Resolvins
32416413 2020. Covid-19 management with inflammation resolving mediators? Perspectives and potential
beta adrenergic antagonists
32388480 2020. Can beta-adrenergic blockers be used in the treatment of COVID-19?
mabs
32534226 2020. Monoclonal antibody as a potential anti-COVID-19.
32514101 2020. First antibody against COVID-19 spike protein enters phase I.
32422645 2020. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
32512271 2020. An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review.
tlr's
32391920 2020. Consider TLR5 for new therapeutic development against COVID-19.
lactoferrin
32529963 2020. Can lactoferrin boost human immunity against COVID-19?
Famotidine
32446698 2020. Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.
32499303 2020. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.
Ursodeoxycholic acid
32505909 2020. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.
Diethylcarbamazine anti-filarial
32492560 2020. Is the anti-filarial drug diethylcarbamazine useful to treat COVID-19?
Nitrofurazoxide
| 32504751 2020. A novel role of nifuroxazide in attenuation of sepsis-associated acute lung and myocardial injuries; role of TLR4/NLPR3/IL-1beta signaling interruption. |
Parthenolide
32472655 2020. Cytokine storm in COVID-19 and parthenolide: preclinical evidence.
Proteasome inh
32443911 2020. Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2.
Lidocaine
32505070 2020. Nebulized Lidocaine in COVID-19, An Hypothesis.
Escin
32441805 2020. Severe Acute Lung Injury Related to COVID-19 Infection: A Review and the Possible Role for Escin.
Methioninase
32503816 2020. Oral Methioninase for Covid-19 Methionine-restriction Therapy.
Thalidomide
C7186126 ä. Proposed use of thalidomide for the cytokine storm of COVID-19
32508009 2020. Thalidomide combined with low-dose short-term glucocorticoid in the treatment of critical Coronavirus Disease 2019.
Valproic acid
32498007 2020. Immunopharmacological management of COVID-19: Potential therapeutic role of valproic acid.
Pentoxyfylline
32449676 2020. COVID-19: Pentoxifylline as a potential adjuvant treatment.
32473070 2020. Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?
32485316 2020. Pentoxifylline and complicated COVID-19: A pathophysiologically based treatment proposal.
PARP inh
32441764 2020. Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for ARDS?
P selectin block
32464083 2020. P-selectin blockade in COVID-19-related ARDS.
Lysosomes, Autophagy, Membranes
32522674 2020. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19.
32522067 2020. Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine.
32521191 2020. Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?
32425923 2020. Could the Inhibition of Endo-Lysosomal Two-Pore Channels (TPCs) by the Natural Flavonoid Naringenin Represent an Option to Fight SARS-CoV-2 Infection?
32449802 2020. May we target double membrane vesicles and oxysterol-binding protein to combat SARS-CoV-2 infection?
Salinomycin
32516655 2020. Pulmonary delivery of nanostructured lipid carriers for effective repurposing of salinomycin as an antiviral agent.
microbiome 2x
32495940 2020. Probiotics and COVID-19: is there any link?
32475223 2020. Antiviral effects of probiotic metabolites on COVID-19.
